Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 October 2025 | Story Lacea Loader

The University of the Free State (UFS) Executive Committee (Exco), Institutional Representative Council (ISRC), and Campus Student Representative Councils (CSRCs) of the three campuses met on 15 October 2025 and reached an agreement regarding the implementation of the phasing out of provisional registration. 
The discussions were held in light of the decision made by the UFS Council on 26 September 2025 to phase out the provisional registration – a decision that led to the recent protest actions on the three campuses the past week. 

In a spirit of working towards a fairer, more equitable, and sustainable financial support system for all academically deserving students, Exco and the student leadership agreed that provisional registration will be phased out over a period of two years (2026-2027). This phased approach allows the university time to assess the risks students are facing with a view to assisting students. This means that from 1 January 2026, all students will be on a fully registered system. 

In recognition of the challenges students face, the outcomes of the meeting reflect the university’s ongoing commitment, and it ensures that all students are supported within a financially sustainable framework. It also reaffirms the university’s commitment to expanding access through enhanced financial support while sustaining the UFS as a national asset for future generations. 

The Exco remains committed to ongoing engagement with student leadership through open dialogue that reflects the university’s values, appreciates the constructive approach taken by the student leadership, and remains dedicated to working collaboratively in the best interest of all students and the broader university community.

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept